Cat allergy immunotherapy - Laboratorios Leti

Drug Profile

Cat allergy immunotherapy - Laboratorios Leti

Alternative Names: Allergenic cat epithelial extract - Laboratorios Leti

Latest Information Update: 29 Mar 2016

Price : $50

At a glance

  • Originator Laboratorios LETI
  • Class Allergens; Antiallergics; Cat allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Hypersensitivity

Most Recent Events

  • 04 Mar 2016 Immunogenicity and pharmacokinetics data from the in vitro studies were presented at the 2016 Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI-2016)
  • 01 Dec 2013 Laboratorios Leti completes a phase II trial in Hypersensitivity (cat allergy) in Spain (NCT01740024)
  • 01 Nov 2012 Phase-II clinical trials in Hypersensitivity (cat allergy) in Spain (Intradermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top